MFM and SJS were supported, in part, by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre at Oxford University Hospitals NHS Trust and University of Oxford. This study was supported by a grant from the National Health Service Blood and Transplant Research and Development Committee (PG04-5) and the Australian Red Cross Blood Service and run by the NHSBT/MRC Clinical Studies Unit.
Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial
Article first published online: 15 MAY 2014
© 2014 AABB
Volume 54, Issue 10, pages 2394–2403, October 2014
How to Cite
Campbell, H. E., Estcourt, L. J., Stokes, E. A., Llewelyn, C. A., Murphy, M. F., Wood, E. M., Stanworth, S. J. and TOPPS Study Investigators (2014), Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion, 54: 2394–2403. doi: 10.1111/trf.12697
Trial Registration: ISRCTN08758735.
- Issue published online: 10 OCT 2014
- Article first published online: 15 MAY 2014
- Manuscript Accepted: 2 FEB 2014
- Manuscript Revised: 28 JAN 2014
- Manuscript Received: 14 OCT 2013
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre at Oxford University Hospitals NHS Trust
- University of Oxford
- National Health Service Blood and Transplant Research and Development Committee. Grant Number: PG04-5
- Australian Red Cross Blood Service
- NHSBT/MRC Clinical Studies Unit
This cost analysis uses data from a randomized trial comparing a no prophylaxis versus prophylactic platelet (PLT) transfusion policy (counts <10 × 109/L) in adult patients with hematologic malignancies. Results are presented for all patients and separately for autologous hematopoietic stem cell transplantation (HSCT) (autoHSCT) and chemotherapy/allogeneic HSCT (chemo/alloHSCT) patients.
Study Design and Methods
Data were collected to 30 days on PLT and red blood cell (RBC) transfusions, major bleeds, serious adverse events, critical care, and hematology ward stay. Data were costed using 2011 to 2012 UK unit costs and converted into US$. Sensitivity analyses were performed on uncertain cost variables.
Across the whole trial no prophylaxis saved costs compared to prophylaxis: −$1760 per patient (95% confidence interval [CI], −$3250 to −$249; p < 0.05). For autoHSCT patients there was no cost difference between arms: −$110 per patient (95% CI, −$1648 to $1565; p = 0.89). For chemo/alloHSCT patients no prophylaxis cost significantly less than prophylaxis: −$5686 per patient (95% CI, −$8580 to −$2853; p < 0.01). The cost impact of no prophylaxis differed significantly between subgroups. Sensitivity analyses varying daily treatment costs and ward stay for chemo/alloHSCT patients reduced cost differences to −$941 per patient (p = 0.21) across the whole trial and −$2927 per patient (p < 0.05) in chemo/alloHSCT subgroup.
It is unclear whether a no-prophylaxis policy saves costs overall. In chemo/alloHSCT patients cost savings are apparent but their magnitude is sensitive to a number of variables and must be considered alongside clinical data showing increased bleeding rates. In autoHSCT patients savings generated through lower PLT use in no-prophylaxis arm were offset by cost increases elsewhere, for example, additional RBC transfusions. Cost-effectiveness analyses of alternative PLT transfusion policies simultaneously considering costs and patient-reported outcomes are warranted.